Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Janux Therapeutics, Inc. (JANX) had Weighted-Average Shares Outstanding (Diluted) of 53.75M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$10.59M |
|
$-68.99M |
|
-- |
|
$10.59M |
|
$109.44M |
|
$-98.85M |
|
$29.85M |
|
$-68.99M |
|
$-68.99M |
|
$-68.99M |
|
$-68.99M |
|
$-68.99M |
|
$-68.99M |
|
$-98.85M |
|
$-107.37M |
|
53.75M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
53.75M |
$-1.28 |
|
$-1.28 |
|
| Balance Sheet Financials | |
$1.03B |
|
$4.86M |
|
$27.85M |
|
$1.06B |
|
$17.46M |
|
-- |
|
$21.28M |
|
$38.73M |
|
$1.02B |
|
$1.02B |
|
$1.02B |
|
59.06M |
|
| Cash Flow Statement Financials | |
$-43.81M |
|
$-258.02M |
|
$713.24M |
|
$20.02M |
|
$431.42M |
|
$411.40M |
|
$33.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
59.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-933.58% |
|
-933.58% |
|
-1014.09% |
|
-651.62% |
|
-651.62% |
|
$-44.17M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-6.75% |
|
-6.75% |
|
-6.50% |
|
-6.75% |
|
$17.32 |
|
$-0.82 |
|
$-0.82 |
|